A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (1) , 47-53
- https://doi.org/10.1111/j.1538-7836.2003.00516.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture SurgeryNew England Journal of Medicine, 2001
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- Deep-vein thrombosisThe Lancet, 1999
- Safety of Treatment with Oral Anticoagulants in the ElderlyDrugs & Aging, 1999
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at HomeNew England Journal of Medicine, 1996
- Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1992
- Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosisThe Lancet, 1992
- Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin IIIThrombosis Research, 1977